Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 157-165 , February 2010

Tumor uptake of 68Ga-DOTA-Tyr3-octreotate: animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model

  • François-Xavier Hanin

      Affiliations

    • Molecular Imaging and Experimental Radiotherapy Unit (MIER), Université Catholique de Louvain, B-1200 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 7642561; fax: +32 2 7645408.
    • ,
  • Stanislas Pauwels

      Affiliations

    • Molecular Imaging and Experimental Radiotherapy Unit (MIER), Université Catholique de Louvain, B-1200 Brussels, Belgium
    • ,
  • Anne Bol

      Affiliations

    • Molecular Imaging and Experimental Radiotherapy Unit (MIER), Université Catholique de Louvain, B-1200 Brussels, Belgium
    • ,
  • Wout Breeman

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • ,
  • Marion de Jong

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • ,
  • François Jamar

      Affiliations

    • Molecular Imaging and Experimental Radiotherapy Unit (MIER), Université Catholique de Louvain, B-1200 Brussels, Belgium

Received 13 August 2009 ,Revised 18 September 2009 ,Accepted 21 September 2009.

References 

  1. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–282
  2. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–731
  3. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323(18):1246–1249
  4. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32(4):478–485
  5. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28(12):1751–1757
  6. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)–a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30(4):510–518
  7. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(Suppl 1):172S–178S
  8. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 2000;7(9):971–994
  9. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(Suppl 2):S23–S29
  10. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41(10):1704–1713
  11. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110–122
  12. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319–1325
  13. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439–1447
  14. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46(Suppl 1):83S–91S
  15. Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant. 2004;19(9):2275–2281
  16. Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med. 2006;47(3):432–436
  17. Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, et al. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun. 2008;29(3):283–290
  18. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology. 1996;137(9):4046–4049
  19. Froidevaux S, Hintermann E, Torok M, Macke HR, Beglinger C, Eberle AN. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res. 1999;59(15):3652–3657
  20. Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging. 2007;34(4):532–540
  21. Bol A, Melin JA, Vanoverschelde JL, Baudhuin T, Vogelaers D, De Pauw M, et al. Direct comparison of [13N]ammonia and [15O]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres. Circulation. 1993;87(2):512–525
  22. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ, et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med. 1995;36(4):623–627
  23. Jonard P, Jamar F, Walrand S, Labar D, Mathieu I, Smith C, et al. Effect of peptide amount on biodistribution of 86Y-DOTA-Tyr3-octreotide (SMT487). J Nucl Med, Proceedings of the 47th SNM annual meeting 2000;260P.
  24. Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G. Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. Drug Metab Dispos. 1989;17(6):699–703
  25. Marbach P, Briner U, Lemaire M, Schweitzer A, Terasaki T. From somatostatin to Sandostatin: pharmacodynamics and pharmacokinetics. Digestion. 1993;54(Suppl 1):9–13
  26. FDA approved package insert of OctreoScan®. downloaded from http://www.octreoscan.com/OctreoscanPI.pdfon september, 14, 2009
  27. Dorr U, Rath U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ, et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med. 1993;20(5):431–433
  28. Janson ET, Kalkner KM, Eriksson B, Westlin JE, Oberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol. 1999;26(8):877–882
  29. Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005;46(8):1310–1316
  30. Goglia U, Ferone D, Sidoti M, Spaziante R, Dadati P, Ravetti JL, et al. Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. Pituitary. 2008;11(1):93–102
  31. Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45(7):836–844
  32. Highlights of Prescribing information for Sandostatin® LAR® Depot. available at http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin_lar.pdfdownloaded on September, 14, 2009
  33. Bao A, Goins B, Dodd GDr, Soundararajan A, Santoyo C, Otto RA, et al. Real-time iterative monitoring of radiofrequency ablation tumor therapy with 15O-water PET imaging. J Nucl Med. 2008;49(10):1723–1729
  34. Kunz P, Hoffend J, Altmann A, Dimitrakopoulou-Strauss A, Koczan D, Eisenhut M, et al. Angiopoietin-2 overexpression in morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes. J Nucl Med. 2006;47(9):1515–1524
  35. Schmidt K, Hoffend J, Altmann A, Kiessling F, Strauss L, Koczan D, et al. Troponin I overexpression inhibits tumor growth, perfusion, and vascularization of morris hepatoma. J Nucl Med. 2006;47(9):1506–1514
  36. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, et al. Angiostatin overexpression in Morris hepatoma results in decreased tumor growth but increased perfusion and vascularization. J Nucl Med. 2006;47(3):543–551
  37. Croteau E, Benard F, Bentourkia M, Rousseau J, Paquette M, Lecomte R. Quantitative myocardial perfusion and coronary reserve in rats with 13N-ammonia and small animal PET: impact of anesthesia and pharmacologic stress agents. J Nucl Med. 2004;45(11):1924–1930

PII: S0969-8051(09)00245-5

doi: 10.1016/j.nucmedbio.2009.09.006

Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 157-165 , February 2010

Article Tools

* Image Usage & Resolution